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Abstract 
Objective: To describe the recent legislation in Tennessee and subsequent development and implementation of state-wide 
buprenorphine treatment guidelines. 
Practice Innovation: In 2016, Tennessee began licensing office-based opioid treatment (OBOT) clinics. Due to initial licensing criteria, 
not all providers were required to be licensed with the Department of Mental Health and Substance Abuse Services (TDMHSAS). The 
gap in licensing made it difficult to ensure an appropriate standard of care was being met by all addiction treatment providers. 
Therefore, the state developed legislation that allowed for the creation of best practice guidelines to encompass all providers of 
buprenorphine in the state of Tennessee, not just the licensed OBOT clinics. The guidelines define what the standard of care should 
entail while treating this vulnerable addiction population. 
Results: Tennessee legislation granted the formation of a committee to create the Tennessee Nonresidential Buprenorphine Treatment 
Guidelines. The committee was comprised of physicians, pharmacists, lawyers, law enforcement, and state officials. The finalized 
guidelines were published and effective January 1, 2018, and adopted as policy by the boards of medical examiners, osteopathic 
examination, and pharmacy shortly thereafter. The guidelines are now enforceable by the boards and give them the ability to discipline 
physicians who practice outside the standard of care. 
Conclusion: Tennessee legislation provides a model for other states to take action in combating this opioid crisis by not only increasing 
access to addiction treatment, but increasing access to quality care.  
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In 2016, the CDC estimated 2.1 million people had an opioid 
use disorder. There were more than 42,000 opioid overdose 
deaths in the United States1,2, 1,186 of those overdose deaths 
were in Tennessee alone3. Being in the midst of an opioid 
pandemic, many states are taking action to help combat this 
opioid crisis including stricter penalties for overprescribing, 
over-dispensing of opioids, and increasing prevention 
strategies. Tennessee is attempting to increase access to 
addiction treatment, by not only increasing access to care but 
access to quality care. 
 
According to the Substance Abuse and Mental Health Services 
Administration (SAMHSA), medication-assisted treatment 
(MAT) is the use of FDA-approved medications, in combination 
with counseling and other behavioral therapies, to provide a 
whole-patient approach to the treatment of substance use 
disorders. Medication is one tool that can be used as adjunct  
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to counseling or other behavioral therapies. MAT services can 
be provided in opioid treatment programs (OTPs), which are 
more commonly known as “methadone clinics”, office-based 
opioid treatment (OBOT) clinics, and in inpatient settings. The 
medications used in these facilities are methadone, 
naltrexone, or buprenorphine. To be eligible to prescribe 
buprenorphine for the treatment of opioid use disorder (OUD), 
a prescriber must apply and receive their DATA 2000 waiver, 
or better known as their “X” DEA number. Buprenorphine 
exerts a mixed agonist-antagonist action on the CNS opiate 
receptors4.  Advantages of using buprenorphine include 
increased safety in cases of overdose, when compared to 
methadone, and can be filled at a pharmacy.  The MAT 
approach has been shown to improve patient survival, 
increase retention in treatment, decrease illicit opiate use and 
other criminal activity, and increase patients’ ability to gain 
and maintain employment5. The ultimate goal of MAT is to 
improve the patients’ quality of life and help them to enter full 
recovery5.  
 
In 2016, Tennessee Department of Mental Health and 
Substance Abuse Services (TDMHSAS) began licensing office-
based opioid treatment (OBOT) clinics to better regulate the 
standard of care which buprenorphine clinics provided. 
However, due to the licensing requirements, not all DATA 2000 
waived physicians were required to apply for a licensure. As a 
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state, Tennessee began to see an influx of clinics providing only 
prescription services without counseling or behavioral therapy 
services, to patients with an opioid use disorder while staying 
below the licensing criteria. This made it difficult to regulate 
these clinics and ensure patients were receiving appropriate 
care. As a result, the state then set forth to establish the 
“adequate care” standard for buprenorphine treatment of 
opioid use disorder with the development of legislation that 
would allow for the creation of best practice guidelines to 
encompass all providers of buprenorphine in the state of 
Tennessee, not just the licensed OBOT clinics. 
 
As of March 2018, only four states, including Tennessee, have 
buprenorphine treatment guidelines that are endorsed by 
their state legislature6,7,8. Other states have buprenorphine 
treatment guidelines created by institutions within the state, 
but do not have support from state legislature. These latter 
states include the Baltimore Buprenorphine Initiative 
developed by the Baltimore City Health Department, 
Baltimore Substance Abuse Systems, and HealthCare Access 
Maryland9. Of importance, most states do have guidelines for 
the treatment of opioid use disorder, which includes sections 
addressing the use of buprenorphine. However, these 
documents do not address buprenorphine treatment alone in 
great detail, typically only devoting a few paragraphs to the 
matter or referring providers to the SAMHSA guidelines. The 
SAMHSA guidelines are thorough; however, they do not 
address some important issues relevant to practice, such as 
guidance on interdisciplinary patient care. For example, the 
role of the pharmacist in the treatment of opioid use disorders 
is not clearly established in these guidelines.  Additionally, 
further guidance was needed on how to initiate pharmacist-
led discussions with patients, how to collaborate with 
providers, and how to determine what constitutes a high 
quality clinic and provider.  For this reason, the Tennessee 
Nonresidential Buprenorphine Treatment Guidelines aim to 
address many aspects of treatment including assessment, 
diagnosis, maintenance, tapering, relapse indicators, 
pharmacist involvement, and provides an extensive list of 
resources for providers who treat substance use disorders. The 
guidelines were created by an expert panel of physicians who 
specialize in treating substance use disorders, law 
enforcement, pharmacists, lawyers, and state officials. The 
guidelines were grounded in evidence from SAMHSA10, the 
American Society of Addiction Medicine (ASAM)11, and the 
American Board of Preventative Medicine. 
 
Tennessee Senate Bill 070912 
There are two core elements of the Tennessee legislation:  
1. Development of Nonresidential Treatment Guidelines for the 
Use of Buprenorphine 
The Department of Mental Health and Substance Abuse 
Services, in collaboration with the Department of Health will 
develop recommended nonresidential treatment guidelines. 
The guidelines developed will be used by practitioners, 
prescribing buprenorphine-containing products, in Tennessee 
as a guide for caring for patients with opioid use disorder in a 
nonresidential, outpatient setting.  
 
2. Publishing and Updating Requirements of the Guidelines 
Beginning in 2019, the guidelines will be reviewed and updated 
by September 30 of each year. The guidelines are posted on 
both the TN Department of Mental Health and Substance 
Abuse Services and the Department of Health’s websites. 
When the guidelines are updated each year, the finished 
product must be provided to the chairs of the Health 
Committee of the House of Representatives and the Health 
and Welfare Committee of the Senate. 
 
The Legislative Process 
The bill itself encountered no opposition as it made its way 
through the legislature, after questions and concerns were 
clarified through committee hearings. It passed unanimously 
in both the House and Senate, was signed by the Governor on 
April 7, 2017, and became Public Chapter 112 on April 19, 
2017. The guidelines were developed and took effect on 
January 1, 2018.  
 
The Tennessee legislature raised questions throughout the 
hearings. First, representatives asked for clarification on the 
difference between the OBOT rules that passed the year prior 
and the need for best practice guidelines. The Department of 
Mental Health and Substance Abuse Services explained the 
need for the guidelines based on issues with gaps in licensure 
and inadequate care being provided by some clinicians in the 
community. The growing need for access to good, quality 
substance use disorder care further provided evidence of the 
necessity for the development of best practice guidelines.  
 
Another question surrounded the genesis of the legislation. 
Some expressed concern for overregulation of the profession 
of medicine. Explanation was given expressing the treatment-
focused approach by the Department of Mental Health and 
Substance Abuse Services is and how development of these 
guidelines would establish a minimum standard of care that 
was not previously being met.   
 
The legislature requested a copy of the guidelines and any 
revisions of the guidelines developed be provided to the chairs 
of the Health Committee of the House of Representatives and 
the Health and Welfare Committee of the Senate. The 
guidelines and revisions must be posted to the websites of the 
Department of Mental Health and Substance Abuse Services 
and the Department of Health.  
 
The final question asked for clarification whether the bill would 
create a committee that would in turn create the guidelines. 
The Department of Mental Health and Substance Abuse 
Services, in conjunction with the Department of Health, invited 
appropriate addiction physicians, alcohol and substance use 
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counselors, law enforcement, pharmacists, and other 
government entities to form a committee to develop the 
nonresidential buprenorphine treatment best practice 
guidelines.  
 
Guideline Development 
The commissioners of Mental Health and Substance Abuse 
Services and Health convened a group of expert providers and 
stakeholders in substance abuse treatment. The committee 
consisted of representatives from residential inpatient 
treatment settings, law enforcement, healthcare providers 
specialized in treating opioid use disorders, pharmacists, 
lawyers, state officials, and patient advocates. The committee 
convened was rather large, and opted to create a smaller, 
working group to do the bulk of the work in the development 
of the guidelines. The working group met on several occasions, 
for several hours at a time, to work through the formation of 
the guidelines. Once a final draft was prepared, the guidelines 
were brought back to the larger group for wordsmithing and 
finalization. The finished product was then presented to the 
commissioners of mental health and health for final approval 
and publication.  
 
After their publication, the Tennessee Nonresidential 
Buprenorphine Treatment Guidelines were presented to the 
board of medical examiners, osteopathic examination, and 
pharmacy, respectively; each board adopted the guidelines as 
policy and provided a link to the guidelines on their respective 
websites. This adoption allows the boards to take action 
against licensees who practice outside the guidelines without 
proper documentation. The guidelines were not presented to 
the board of nursing due to their inability to prescribe or 
dispense buprenorphine in the state of Tennessee. 
https://www.tn.gov/content/dam/tn/mentalhealth/documen
ts/2018_Buprenorphine_Treatment_Guidelines.PDF 
 
Conclusion 
Public Chapter 112 grants the Department of Mental Health 
and Substance Abuse Services and the Department of Health 
the authority to create guidelines for the use of buprenorphine 
for opioid use disorder in a nonresidential setting12. As such, it 
provides a potential model for other states to pursue in the 
years ahead. The entire process took approximately a year and 
a half from the beginning development of the legislation in 
November 2016 to the final completion and publication of the 
guidelines in January 2018. The guideline committee worked 
for approximately six months to progress from a working draft 
to the final document. Though we encountered no opposition 
overall in this endeavor, the legislature did have some 
questions regarding regulations and the genesis of the 
legislation. By soliciting comment and bringing key 
stakeholders to the table early on in the process, we 
developed a collaborative approach to addressing and 
resolving any technical or philosophical issues that may have 
been potential barriers. Our department also leveraged 
existing relationships with advocates within the substance use 
disorder treatment community to garner support for the 
legislation, facilitating its passage. Other jurisdictions looking 
to implement similar legislation may also benefit from utilizing 
community resources, such as medical provider association 
and continuing education events, to provide education to 
healthcare providers. It is essential to work collectively and 
collaboratively with multiple state departments, community 
partners, the general public and healthcare providers to 
ensure all potential barriers are identified and discussed.  
 
The guidelines were adopted as policy by the boards of 
Medical Examiners, Osteopathic Examination, and Pharmacy 
to allow for enforcement. It was self-evident that opioid 
deaths were a problem in Tennessee; therefore it was our aim 
not to prove there was a problem, but rather to provide an 
interdisciplinary approach as part of the solution. Our hope 
with this legislation, and subsequent guideline development 
and adoption, is that the standard of care in outpatient, 
nonresidential substance use disorder treatment will be 
elevated and allow for the residents of Tennessee to received 
quality substance use disorder care. By addressing the opioid 
crisis from an access to care standpoint, we hope to make a 
positive impact by decreasing the number of overdose deaths 
in our state. Moving forward, the guidelines will be updated 
yearly, giving the Department and the community the 
opportunity to evaluate its relevance and applicability in 
improving patient care. The guidelines will continue to be an 
ever evolving, living document with the aim to improve patient 
care and substance use disorder treatment.  
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